Accès gratuit
Pré-publication électronique
Dans une revue
Colon Rectum
Section Dossier thématique / Thematic file
DOI https://doi.org/10.3166/cer-2020-0131
Publié en ligne 29 juillet 2020
  • de Martel C, Ferlay J, Franceschi S, et al (2012) Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 13:607–15 [CrossRef] [PubMed] [Google Scholar]
  • Islami F, Ferlay J, Lortet-Tieulent J, et al (2017) International trends in anal cancer incidence rates. Int J Epidemiol. 46:924–38 [CrossRef] [PubMed] [Google Scholar]
  • Giuliano AR, Nyitray AG, Kreimer AR, et al (2015) EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirusrelated cancer incidence by gender and anatomic site of infection. Int J Cancer 136:2752–60 [CrossRef] [PubMed] [Google Scholar]
  • De Vuyst H, Clifford GM, Nascimento MC, et al (2009) Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 124:1626–36 [CrossRef] [PubMed] [Google Scholar]
  • Boman BM, Moertel CG, O’Connell MJ, et al (1984) Carcinoma of the anal canal: a clinical and pathologic study of 188 cases. Cancer 54:114–25 [CrossRef] [PubMed] [Google Scholar]
  • Peiffert D (2000) Radiochimiothérapie du cancer épidermoïde du canal anal. Ann Chir 125:717–25 [CrossRef] [PubMed] [Google Scholar]
  • Nigro ND, Vaitkevicius VK, Considine B (1974) Combined therapy for cancer of the anal canal. Colon Rectum 27:763–6 [CrossRef] [Google Scholar]
  • Nigro ND, Vaitkevicius VK, Herskovic AM (1989) Preservation of function in the treatment of cancer of the anus. In: De Vita VT, Hellmann S, Rosenberg SA (eds) Important advances in oncology. JB Lippincot, Philadelphia, pp 161–77 [PubMed] [Google Scholar]
  • Sischy B, Dogget RLS, Krall JM, et al (1989) Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group study n° 8314. J Nat Can Inst 81:850–6 [CrossRef] [Google Scholar]
  • Michaelson RA, Magill G, Quan SHQ, et al (1983) Preoperative chemotherapy and radiation therapy in the management of anal epidermoid carcinoma. Cancer 51:390–5 [CrossRef] [PubMed] [Google Scholar]
  • Cummings BJ, Keane TJ, O’Sullivan B, et al (1991) Epidermoid anal cancer: treatment by radiation alone or by radiation and 5- fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys 21:1115–25 [CrossRef] [PubMed] [Google Scholar]
  • Flam M, John MJ, Mowry PA, et al (1987) Definitive combined modality therapy of carcinoma of the anus. Dis Colon Rectum 30:495–502 [CrossRef] [PubMed] [Google Scholar]
  • Habr-Gramma A, Da Silva E, Sousa AH, et al (1989) Epidermoid carcinoma of the anal canal. Results of treatment by combined chemotherapy and radiation therapy. Dis Colon Rectum 32:773–7 [CrossRef] [PubMed] [Google Scholar]
  • Hughes LL, Rich TA, Delclos L, et al (1989) Radiotherapy for anal cancer. Experience from 1979–1987. Int J Radiat Oncol Biol Phys 17:1153–60 [CrossRef] [PubMed] [Google Scholar]
  • Marti MC, Pipard G (1989) Epidermoid carcinoma of the anal canal. Value of a multidisciplinary approach. Chirurgie 115:715–22 [Google Scholar]
  • Tanum G, Tveit K, Karlsen KO, Hauer-Jensen M (1991) Chemotherapy and radiation therapy for anal carcinoma. Cancer 67:2462–6 [CrossRef] [PubMed] [Google Scholar]
  • Northover J, Glynne-Jones R, Sebag-Montefiore D, et al (2010) Chemoradiation for the treatment of epidermoid anal cancer: 13- year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer 102:1123–8 [CrossRef] [PubMed] [Google Scholar]
  • Bartelink H, Roelofsen F, Eschwege F, et al (1997) Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 15:2040–9 [CrossRef] [PubMed] [Google Scholar]
  • Lepinoy A, Lescut N, Puyraveau M, et al (2015) Evaluation of a 36 Gy elective node irradiation dose in anal cancer. Radiother Oncol 116:197–201 [CrossRef] [PubMed] [Google Scholar]
  • Ortholan C, Resbeut M, Hannoun-Levi JM, et al (2012) Anal canal cancer: management of inguinal nodes and benefit of prophylactic inguinal irradiation (CORS-03 Study). Int J Radiat Oncol Biol Phys 82:1988–95 [CrossRef] [PubMed] [Google Scholar]
  • Wright JL, Patil SM, Temple LKF, et al (2010) Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning. Int J Radiat Oncol Biol 78:1064–72 [CrossRef] [Google Scholar]
  • Peiffert D, Tournier-Rangeard L, Gérard JP, et al (2012) Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 Trial. J Clin Oncol 30:1941–8 [CrossRef] [PubMed] [Google Scholar]
  • Konski A, Garcia M Jr., John M, et al (2008) Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. Int J Radiat Oncol Biol Phys 72:114–8 [CrossRef] [PubMed] [Google Scholar]
  • Weber DC, Kurtz JM, Allal AS (2001) The impact of gap duration on local control in anal canal carcinoma treated by splitcourse radiotherapy and concomitant chemotherapy. Int J Radiat Oncol Biol Phys 50:675–80 [CrossRef] [PubMed] [Google Scholar]
  • Glynne-Jones R, Sebag-Montefiore D, Adams R, et al (2011) “Mind the gap--” the impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal Cancer Trial (ACT I). Int J Radiat Oncol Biol Phys 81:1488–94 [CrossRef] [PubMed] [Google Scholar]
  • Constantinou EC, Daly W, Fung CY, et al (1997) Time-dose considerations in the treatment of anal cancer. Int J Radiat Oncol Biol 39:651–7 [CrossRef] [Google Scholar]
  • Peiffert D, Créhange G, Vendrely V, et al (2016) Radiothérapie des cancers du canal anal. Cancer Radiother 20:S183–8 [CrossRef] [PubMed] [Google Scholar]
  • Kachnic LA, Winter K, Myerson RJ, et al (2013) RTOG 0529: a phase II evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 86:27–33 [CrossRef] [PubMed] [Google Scholar]
  • Hannoun-Levi JM, Ortholan C, Resbeut M, et al (2011) Highdose split-course radiation therapy for anal cancer: outcome analysis regarding the boost strategy (CORS-03 study). Int J Radiat Oncol Biol Phys 80:712–20 [CrossRef] [PubMed] [Google Scholar]
  • Moureau-Zabotto L, Ortholan C, Hannoun-Levi JM, et al (2013) Role of brachytherapy in the boost management of anal carcinoma with node involvement (CORS-03 study). Int J Radiat Oncol Biol Phys 85:e135–42 [CrossRef] [PubMed] [Google Scholar]
  • Flam M, John M, Pajak TF, et al (1996) Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. JCO 14:2527–39 [CrossRef] [PubMed] [Google Scholar]
  • James RD, Glynne-Jones R, Meadows HM, et al (2013) Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous- cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol 14:516–24 [CrossRef] [PubMed] [Google Scholar]
  • Ajani JA, Winter KA, Gunderson LL, et al (2008) Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 299:1914–21 [CrossRef] [PubMed] [Google Scholar]
  • Gunderson LL, Winter KA, Ajani JA, et al (2012) Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol 30:4344–51 [CrossRef] [PubMed] [Google Scholar]
  • Goodman KA, Julie D, Cercek A, et al (2017) Capecitabine with mitomycin reduces acute hematologic toxicity and treatment delays in patients undergoing definitive chemoradiation using intensity modulated radiation therapy for anal cancer. Int J Radiat Oncol Biol Phys 98:1087–95 [CrossRef] [PubMed] [Google Scholar]
  • Gordeev S, Rasulov A, Gordunova V, et al (2017) A pilot study of intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy (CT) with paclitaxel, capecitabine and mimomycin C for squamous cell anal carcinoma (SCAC). J Clin Oncol 33: e14501 [Google Scholar]
  • Roed H, Engelholm SA, Svendsen LB, et al (1996) Pulsed dose rate (PDR) brachytherapy of anal carcinoma. Radiother Oncol 41:131–4 [CrossRef] [PubMed] [Google Scholar]
  • Quéro L, Duval X, Abramowitz L (2014) Cancer de l’anus chez les patients séropositifs pour le VIH. Bull Cancer 101:1034–9 [CrossRef] [PubMed] [Google Scholar]
  • De Bari B, Lestrade L, Chekrine T, et al (2012) Faut-il adapter le traitement du carcinome du canal anal pour les patients âgés ? Analyse rétrospective de la toxicité dans un centre français et revue de la littérature. Cancer Radiother 16:52–7 [CrossRef] [PubMed] [Google Scholar]
  • Charnley N, Choudhury A, Chesser P, et al (2005) Effective treatment of anal cancer in the elderly with low-dose chemoradiotherapy. Br J Cancer 92:1221–5 [CrossRef] [PubMed] [Google Scholar]
  • Myerson RJ, Kong F, Birnbaum EH, et al (2001) Radiation therapy for epidermoid carcinoma of the anal canal, clinical and treatment factors associated with outcome. Radiother Oncol J Eur Soc Ther Radiol Oncol 61:15–22 [CrossRef] [Google Scholar]
  • Zilli T, Schick U, Ozsahin M, et al (2012) Node-negative T1-T2 anal cancer: radiotherapy alone or concomitant chemoradiotherapy? Radiother Oncol 102:62–7 [CrossRef] [PubMed] [Google Scholar]
  • De Bari B, Jumeau R, Bouchaab H, et al (2016) Efficacy and safety of helical tomotherapy with daily image guidance in anal canal cancer patients. Acta Oncol 55:767–73 [CrossRef] [PubMed] [Google Scholar]
  • Matthews JHL, Burmeister BH, Borg M, et al (2011) T1-2 anal carcinoma requires elective inguinal radiation treatment — The results of Trans Tasman Radiation Oncology Group study TROG 99.02. Radiother Oncol 98:93–8 [CrossRef] [PubMed] [Google Scholar]
  • Franco P, Arcadipane F, Ragona R, et al (2016) Early-stage Node-negative (T1-T2N0) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy. Anticancer Res 36:1943–8 [PubMed] [Google Scholar]
  • Shridhar R, Shibata D, Chan E, et al (2015) Anal cancer: current standards in care and recent changes in practice. CA Cancer J Clin 65:139–62 [CrossRef] [PubMed] [Google Scholar]
  • Renehan AG, Saunders MP, Schofield PF, et al (2005) Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. Br J Surg 92:605–12 [CrossRef] [PubMed] [Google Scholar]
  • Eng C, Messick C, Glynne-Jones R (2019) The management and prevention of anal squamous cell carcinoma. Am Soc Clin Oncol Educ Book 39:216–25 [CrossRef] [PubMed] [Google Scholar]
  • Bernardi MP, Ngan SY, Michael M, et al (2015) Molecular biology of anal squamous cell carcinoma: implications for future research and clinical intervention. Lancet Oncol 16:e611–21 [CrossRef] [PubMed] [Google Scholar]
  • Sparano JA, Lee JY, Palefsky J, et al (2017) Cetuximab plus chemoradiotherapy for HIV-associated anal carcinoma: a phase II AIDS Malignancy Consortium trial. J Clin Oncol 35:727–33 [CrossRef] [PubMed] [Google Scholar]
  • Garg MK, Zhao F, Sparano JA, et al (2017) Cetuximab plus chemoradiotherapy in immunocompetent patients with anal carcinoma: a phase II Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group trial (E3205). J Clin Oncol 35:718–26 [CrossRef] [PubMed] [Google Scholar]
  • Vendrely V, Lemanski C, Gnep K, et al (2019) Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: results of a phase I dose-escalation study with panitumumab (FFCD 0904). Radiother Oncol 140:84–9 [CrossRef] [PubMed] [Google Scholar]
  • Safran H, Leonard KL, Perez K, et al (2018) Tolerability of ADXS11-001 Lm-LLO Listeria-based immunotherapy with mitomycin, fluorouracil, and radiation for anal cancer. Int J Radiat Oncol Biol Phys 100:1175–8 [CrossRef] [PubMed] [Google Scholar]
  • Cacheux W, Rouleau E, Briaux A, et al (2016) Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection. Br J Cancer 114:1387–94 [CrossRef] [PubMed] [Google Scholar]
  • Schneider R, Bannister AJ, Myers FA, et al (2004) Histone H3 lysine 4 methylation patterns in higher eukaryotic genes. Nat Cell Biol 6:73–7 [CrossRef] [PubMed] [Google Scholar]
  • Kourou K, Exarchos TP, Exarchos KP, et al (2015) Machine learning applications in cancer prognosis and prediction. Comput Struct Biotechnol J 13:8–17. doi: 10.1016/j.csbj.2014.11.005. eCollection 2015 [CrossRef] [PubMed] [Google Scholar]
  • Abernethy AP, Etheredge LM, Ganz PA, et al (2010) Rapidlearning system for cancer care. J Clin Oncol 28:4268–74 [CrossRef] [PubMed] [Google Scholar]
  • Vendrely, V, Lemanski C, François E, et al (2018) OC-0284: first results of the French cohort ANABASE : treatment and outcome in non-metastatic anal cancer. Radiother Oncol 127:S146 [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.